

FOI Request Response information

FOI request reference:	2017/405
Date request received:	20/12/2017
Date request responded to:	08/01/2018
Category:	Pharmacy
Tags:	Biologics, biosimilar, prescribing, drugs, arthritis, spondylitis, psoriasis, crohns, colitis

Request Detail:

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below.

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Psoriasis
- Hidradenitis Suppurativa
- Crohn's disease
- Ulcerative Colitis

Number of patients treated	Rheumatoid Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis	Psoriasis	Hidradenitis Suppurativa	Crohn's disease	Ulcerative Colitis
TOTAL							
Abatacept [Orencia]							
Adalimumab [Biosimilar]							
Adalimumab [Humira]							
Apremilast [Otezla]							
Baricitinib [Olumiant]							
Brodalumab [Kyntheum]							
Certolizumab [Cimzia]							
Dimethyl fumarate [Skilarence]							
Etanercept [Enbrel]							
Etanercept Biosimilar [Benepali or Erelzi]							
Golimumab [Simponi]							
Guselkumab [Tremfya]							

Infliximab [Remicade]							
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]							
Ixekizumab [Taltz]							
Rituximab [Mabthera]							
Rituximab Biosimilar [Rixathon or Truxima]							
Sarilumab [Kevzara]							
Secukinumab [Cosentyx]							
Tocilizumab [Ro Actemra]							
Tofacitinib [Xeljanz]							
Ustekinumab [Stelara]							
Vedolizumab [Entyvio]							

Response Detail:

The Trust is unable to provide a response to your recent FOI request as the information is not available electronically and so cannot be provided within the recommended timescales. It would necessitate a manually look through paper records.